These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 34776443

  • 1. Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum.
    Nihashi T, Sakurai K, Kato T, Iwata K, Kimura Y, Ikenuma H, Yamaoka A, Takeda A, Arahata Y, Washimi Y, Suzuki K, Bundo M, Sakurai T, Okamura N, Yanai K, Ito K, Nakamura A, MULNIAD Study Group.
    J Alzheimers Dis; 2022; 85(1):223-234. PubMed ID: 34776443
    [Abstract] [Full Text] [Related]

  • 2. Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease.
    Kang JM, Lee SY, Seo S, Jeong HJ, Woo SH, Lee H, Lee YB, Yeon BK, Shin DH, Park KH, Kang H, Okamura N, Furumoto S, Yanai K, Villemagne VL, Seong JK, Na DL, Ido T, Cho J, Lee KM, Noh Y.
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [Abstract] [Full Text] [Related]

  • 3. Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
    Cody KA, Langhough RE, Zammit MD, Clark L, Chin N, Christian BT, Betthauser TJ, Johnson SC.
    Brain; 2024 Jun 03; 147(6):2144-2157. PubMed ID: 38667631
    [Abstract] [Full Text] [Related]

  • 4. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
    Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.
    Alzheimers Res Ther; 2017 Mar 31; 9(1):25. PubMed ID: 28359327
    [Abstract] [Full Text] [Related]

  • 5. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ, Koscik RL, Jonaitis EM, Allison SL, Cody KA, Erickson CM, Rowley HA, Stone CK, Mueller KD, Clark LR, Carlsson CM, Chin NA, Asthana S, Christian BT, Johnson SC.
    Brain; 2020 Jan 01; 143(1):320-335. PubMed ID: 31886494
    [Abstract] [Full Text] [Related]

  • 6. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A, Schonhaut DR, La Joie R, Kramer JH, Baker SL, Sosa N, Ayakta N, Cantwell A, Janabi M, Lauriola M, O'Neil JP, Gorno-Tempini ML, Miller ZA, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2017 Dec 01; 140(12):3286-3300. PubMed ID: 29053874
    [Abstract] [Full Text] [Related]

  • 7. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD.
    Brain; 2016 May 01; 139(Pt 5):1551-67. PubMed ID: 26962052
    [Abstract] [Full Text] [Related]

  • 8. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
    Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.
    Neuroimage; 2010 Aug 15; 52(2):488-96. PubMed ID: 20385246
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
    Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M, Lussier FZ, Tissot C, Chamoun M, Kang MS, Stevenson J, Massarweh G, Guiot MC, Soucy JP, Gauthier S, Rosa-Neto P.
    Brain; 2021 Dec 16; 144(11):3517-3528. PubMed ID: 34515754
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group.
    Brain; 2012 Jul 16; 135(Pt 7):2126-39. PubMed ID: 22628162
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer's Disease Patients Measured Using [18F] THK-5351.
    Lockhart SN, Baker SL, Okamura N, Furukawa K, Ishiki A, Furumoto S, Tashiro M, Yanai K, Arai H, Kudo Y, Harada R, Tomita N, Hiraoka K, Watanuki S, Jagust WJ.
    PLoS One; 2016 Jul 16; 11(6):e0158460. PubMed ID: 27355840
    [Abstract] [Full Text] [Related]

  • 20. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD, Mintun MS.
    Brain; 2016 May 16; 139(Pt 5):1539-50. PubMed ID: 26936940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.